Carbon Ion Therapy for Pancreatic Cancer: Eligibility, Survival, Cost

Carbon ion therapy for pancreatic cancer is used mostly for locally advanced pancreatic cancer that cannot be removed by surgery and has not spread to distant organs. In Japan, this indication has been covered by public health insurance since April 2022 (an approved treatment). A Japanese multi-institutional study of 72 patients reported a 2-year survival rate of 46% and a median survival of 21.5 months, but a study from Heidelberg, Germany, did not find a survival gain over conventional radiotherapy, and a randomized comparison is still ongoing. This article summarizes only what we could confirm from Japanese and German institutions and journals: eligible stages, number of sessions, survival, side effects and cost. To check eligibility with your own scans and reports first, please use our pancreatic cancer carbon ion therapy consultation.

Who can receive carbon ion therapy for pancreatic cancer, and up to which stage?

Carbon ion therapy (heavy ion therapy) accelerates carbon ions so that they release most of their energy at the depth of the tumor. The principle and the difference from conventional radiotherapy are explained in What Is Carbon Ion Therapy? The pancreas is surrounded by the stomach, duodenum and small intestine, which makes high-dose radiation difficult. Because a carbon ion beam peaks at a set depth and then drops off sharply, it has been tried for tumors in this location.

The English information page of QST Hospital in Japan (formerly the NIRS Hospital) divides eligible pancreatic cancer into three situations:

• Resectable or borderline resectable (before surgery): clinical stage 0 to III
• Locally advanced (other curative treatment difficult): clinical stage I to III
• Local recurrence after surgery: recurrence limited to one area

Stage IV is generally not eligible, although QST Hospital notes that cases with metastasis only to the para-aortic lymph nodes may be considered and advises asking your physician. Patients with metastasis to the liver, lungs, peritoneum or distant lymph nodes, direct invasion of the digestive tract, or a metal biliary stent for jaundice (a plastic stent is acceptable) are excluded. In other words, the answer to "up to which stage" depends less on the stage number than on whether there is distant spread and whether there is enough distance from the bowel. See also our summary Pancreatic cancer carbon ion therapy: eligibility and 12-session schedule.

Sessions and schedule: 8 before surgery, 12 for locally advanced disease

According to QST Hospital, preoperative treatment is 8 sessions over 2 weeks followed by planned surgery, and locally advanced pancreatic cancer that cannot be operated on receives 12 sessions over 3 weeks. The trial leaflet of the Japan Carbon-ion Radiation Oncology Study Group (J-CROS) describes a total of 55.2 Gy (RBE) in 12 sessions combined with the chemotherapy drug gemcitabine. The same leaflet says each irradiation takes 2 to 3 minutes, a visit to the treatment room takes about 20 minutes, and the immobilization device and planning CT are prepared about one week before treatment starts.

The stay in Japan therefore has to cover not only the 3 weeks of irradiation but also the first consultation and the preparation of the device and planning CT (about one week before treatment, according to the leaflet).

How effective is it? Survival data

The survival figures come mainly from Japanese single- and multi-institution studies. Patient groups and combined treatments differ, so the numbers should not be compared directly, and none of them comes from a randomized trial.

In short, carbon ions show strong local control of the irradiated tumor in several studies, but pancreatic cancer often spreads to the liver or peritoneum afterwards, so overall survival depends heavily on chemotherapy and the biology of the disease. In the J-CROS study, only 28% remained free of distant metastasis at 2 years. A randomized trial comparing carbon ions with conventional (photon) radiotherapy is registered internationally (ClinicalTrials.gov NCT03536182) and has not yet reported. Claims that carbon ion therapy "cures" pancreatic cancer are not supported by the evidence.

Side effects and when treatment may not be possible

In the J-CROS multi-institutional study, grade 3–4 acute blood toxicity (such as low white blood cell counts) occurred in 26%, mainly attributed to the chemotherapy; non-blood grade 3 effects were loss of appetite in 2 patients (3%), late grade 3 gastrointestinal toxicity in 1 patient (1%), and there was no late grade 4–5 toxicity. The QST phase I/II study reported one gastric ulcer with bleeding at 10 months. The trial leaflet notes mild loss of appetite and abdominal pain during treatment and, rarely, gastrointestinal bleeding or ulcers afterwards. Side-effect figures for other cancers are in Carbon ion therapy side effects.

The exclusion criteria in the trial leaflet show what to check before a consultation: ascites, direct invasion of the digestive tract visible on endoscopy or imaging, gastric or duodenal ulcers (scars are acceptable), symptomatic interstitial pneumonia, previous radiotherapy to the same area, and poor general condition (ECOG 3 or higher). Criteria used in actual practice may differ by hospital and over time.

Cost and insurance coverage

Since April 2022, particle therapy for unresectable locally advanced pancreatic cancer without distant metastasis has been covered by Japanese public insurance. Before that it was provided as Advanced Medical Care, and the J-CROS leaflet listed the technical fee at that time as 3.14 to 3.5 million yen. QST Hospital's guidance as of June 2024 gives a base amount of 2.375 million yen for insured conditions other than prostate cancer, of which Japanese insured patients pay 10–30%.

Overseas patients are different. People not enrolled in Japanese public insurance cannot use insured care and generally pay the full cost themselves. Published hospital amounts include a self-pay technical fee of 3.85 million yen (tax included, as of 2025-05-01) at QST Hospital and 4.8 million yen plus consumption tax for overseas patients at Osaka Heavy Ion Therapy Center. Pre-treatment tests, hospitalization, chemotherapy, accommodation and interpreting are extra. A hospital-by-hospital comparison is in Carbon ion therapy cost in Japan.

Time matters in pancreatic cancer. If your scans and pathology reports are ready, please contact us to check whether a Japanese institution can review your case.

Checklist before a consultation

• Contrast CT or MRI images on CD from the last month, with radiology reports (the degree of vessel involvement is key)
• Biopsy or cytology report confirming adenocarcinoma
• Chemotherapy record: drug names, start date, number of cycles, response
• Whether you have a biliary stent and its type (metal or plastic), and upper endoscopy results
• Tumor marker (CA19-9) trend, blood tests and general condition
• Questions to ask: Am I in the preoperative, locally advanced or recurrence group? Will chemotherapy be combined? Inpatient or outpatient? Where will follow-up be done after I return home?

Hospitals differ in how they accept overseas patients and which cancers they treat, so please also see Japanese Institutions.

Frequently asked questions

Can stage 4 pancreatic cancer be treated with carbon ions?

If there is metastasis to distant organs such as the liver, lungs or peritoneum, it is generally not eligible. QST Hospital says cases with metastasis only to the para-aortic lymph nodes may be considered, so an individual review of the images is needed.

What is the survival rate of carbon ion therapy for pancreatic cancer?

In a Japanese multi-institutional study of 72 locally advanced cases, 2-year survival was 46% and median survival 21.5 months. A German study, however, did not show better survival than conventional radiotherapy, and randomized results are not yet available.

Is carbon ion therapy better than surgery?

For resectable pancreatic cancer, surgery is the standard. QST Hospital's preoperative carbon ion therapy (8 sessions) is given together with surgery. There is no evidence that it replaces surgery.

Can foreigners pay the Japanese insurance price?

Overseas patients not enrolled in Japanese public insurance are not eligible for insured care and generally pay the full cost. The amount must be confirmed with a hospital quotation.

I have a metal stent. Can I still be treated?

QST Hospital's guidance excludes patients with a metal stent for jaundice, while a plastic stent is acceptable. Please tell us the stent type when you consult.

Sources

• QST Hospital — Pancreatic Cancer (eligibility, results)
• Kawashiro et al., J-CROS 1403 Pancreas multi-institutional study, IJROBP 2018
• Shinoto et al., carbon-ion RT with concurrent gemcitabine, phase I/II, IJROBP
• Liermann et al., Heidelberg Ion Beam Therapy Center, Front Oncol 2021
• ClinicalTrials.gov NCT03536182 — carbon ion vs photon RT, locally advanced pancreatic cancer
• J-CROS locally advanced pancreatic cancer carbon-ion trial leaflet (Japanese)
• QST Hospital carbon-ion therapy guide, as of June 2024 (Japanese)
• Interview, Hyogo Ion Beam Medical Center — 2022 insurance coverage for pancreatic cancer, Medical Note (Japanese)
• QST Hospital treatment costs (Japanese)
• Osaka Heavy Ion Therapy Center treatment costs (Japanese)

General information based on public sources; not a substitute for diagnosis or treatment. Eligibility is decided by the treating physicians. Written by the FTH editorial team.